Regulatory Halt Issued for MYCOF Shares Amid "Unusual Fluctuations" and Disavowal of Inaccurate Article
Summary
The British Columbia Securities Commission (BCSC) has issued a trading halt for Noveris Health Sciences Inc. (MYCOF) securities until April 16, 2026. The BCSC cited "unexplained and unusual fluctuations" in trading volume and market price as the reason for the order. This regulatory action is a highly material negative development, as it prevents investors from trading the stock and signals significant concerns from regulators. Additionally, the company has publicly disavowed an article circulated on March 19, 2026, by John Michaels, specifically clarifying that the article's claim of being "FDA-registered" is inaccurate. This repudiation of false information, particularly concerning regulatory status for a biotechnology company, exacerbates the negative sentiment and raises questions about market integrity and company communications. Noveris states its intention to cooperate fully with the BCSC to resolve the issues.
At the time of this announcement, MYCOF was trading at $1.32 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.01 to $1.40. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: The newswire.ca.